10x Genomics, Inc. (TXG) |
| 69.86 -2.53 (-3.49%) 10-16 16:00 |
| Open: | 72.18 |
| High: | 73.53 |
| Low: | 67.76 |
| Volume: | 2,794,533 |
| Market Cap: | 9,102(M) |
| PE Ratio: | -118.41 |
| Exchange: | NASDAQ Global Select |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 102.81 |
| Resistance 1: | 88.26 |
| Pivot price: | 81.73 |
| Support 1: | 64.73 |
| Support 2: | 53.86 |
| 52w High: | 102.81 |
| 52w Low: | 11.87 |
Headquartered in Pleasanton, California, 10x Genomics, Inc. (founded in 2012 and known as 10X Technologies, Inc. until November 2014) is a prominent life science technology company. The firm specializes in creating and distributing sophisticated instrumentation, essential consumables, and software designed for in-depth analysis of biological systems. Its market presence extends globally, covering North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company's offerings feature Chromium and Chromium Connect instruments, supported by indispensable items such as microfluidic chips, slides, and reagents. A significant portion of their portfolio focuses on single-cell solutions, leveraging their Chromium platforms. These allow for precise measurement of gene activity at the individual cell level (single cell gene expression), detailed assessment of immune cell function and their targets (single cell immune profiling), exploration of DNA's physical organization and epigenetic modifications (single cell Assay for Transposase Accessible Chromatin - ATAC), and the concurrent quantification of both genetic activity and epigenetic programming across tens of thousands of cells in a single experiment (single cell multiome ATAC + gene expression). Additionally, 10x Genomics offers the Visium spatial gene expression solution, which maps gene activity patterns within specific tissue sections and can also facilitate co-detection of gene expression and proteins when paired with immunofluorescence. Their varied customer base includes academic, governmental, biopharmaceutical, and biotechnology organizations, among others.
| EPS | -41200000.000 |
| Book Value | 0.000 |
| PEG Ratio | 51.91 |
| Gross Profit | -6.382 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | -12.18 |
| Return on Assets (ttm) | -15.2 |
| Return on Equity (ttm) | -5.1 |
Sat, 17 Oct 2026
Cathie Wood-Led Ark Invest's Biggest Q3 Winners And Losers — PLTR, NVDA, TXG Led While TSLA, RKLB Dragged - TradingView
Fri, 16 Oct 2026
A Look at 10x Genomics Inc (TXG) After 3.5% Decline -- GF Value $18.31 vs Price $69.86 - GuruFocus
Fri, 16 Oct 2026
10x Genomics, Inc. (TXG) Options Chain - Yahoo Finance - Yahoo! Finance Canada
Tue, 13 Oct 2026
10x Genomics to Report Third Quarter 2026 Financial Results on November 5, 2026 - TradingView
Tue, 13 Oct 2026
A public call on 10x Genomics' results is scheduled for Nov. 5, with a live webcast. - Stock Titan
Mon, 12 Oct 2026
10x Genomics Inc (TXG) Shares Fall 6.8% -- What GF Score of 57 T - GuruFocus
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |